(Total Views: 311)
Posted On: 01/27/2022 10:16:24 AM
Post# of 30015
![Avatar](https://investorshangout.com/images/ProfileImages/1435202243_13345_MANF (200x167).jpg)
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
January 27, 2022 8:23am EST
https://investor.todosmedical.com/news-events...-secondary
January 27, 2022 8:23am EST
https://investor.todosmedical.com/news-events...-secondary
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)